Compare Amgen, Inc. (AMGN) vs Carvana Co (CVNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Carvana Co — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Carvana Co trades at $65.48 (market cap $47.15B). The key difference: Amgen, Inc. is far larger — about 4.2× Carvana Co's market cap, and Amgen, Inc. pays a 2.77% dividend while Carvana Co pays none. Which is the better fit depends on your goals.
| AMGN | CVNA | |
|---|---|---|
Market Cap | $196.12B | $47.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $95.69 |
52-Week Low | $271.18 | $56.27 |
Enterprise Value | $241.41B | $49.80B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Carvana (CVNA) trades at $65.83, down 1.92% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $20.32B in 2025 and net income of $1.41B, though Q2 2026 earnings are pending. Recent corporate actions include stock splits, and positive news highlights expansion into new-car sales and same-day delivery services. The stock shows improving cash flow trends, with operating cash flow reaching $1.04B in 2025.
Outlook: CVNA presents a mixed picture with robust revenue growth and profitability improvements offset by high valuation multiples and technical bearishness. Investment opportunity lies in continued operational scaling and market expansion, but risks include debt levels and competitive pressures. Analysts maintain a bullish consensus price target of $93.92, suggesting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →
